Cyclacel Pharmaceuticals Files Amendment to S-1 Registration Statement

TL;DR

<b>Cyclacel Pharmaceuticals filed an S-1/A amendment on April 19, 2024, updating its registration statement for securities.</b>

AI Summary

Cyclacel Pharmaceuticals, Inc. (BGMSP) filed a Amended IPO Registration (S-1/A) with the SEC on April 19, 2024. Cyclacel Pharmaceuticals, Inc. filed an amendment (Amendment No. 1) to its Form S-1 Registration Statement on April 19, 2024. The filing pertains to the registration of securities under the Securities Act of 1933. The company's principal executive offices are located at 200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922. Cyclacel Pharmaceuticals, Inc. was formerly known as Xcyte Therapies Inc., with a name change effective December 18, 2000. The company is incorporated in Delaware and operates within the Pharmaceutical Preparations industry (SIC code 2834).

Why It Matters

For investors and stakeholders tracking Cyclacel Pharmaceuticals, Inc., this filing contains several important signals. This amendment indicates ongoing efforts by Cyclacel Pharmaceuticals to register securities, which could signal future financing activities or stock offerings. The filing provides updated corporate information, including addresses and former company names, essential for investors and regulatory tracking.

Risk Assessment

Risk Level: low — Cyclacel Pharmaceuticals, Inc. shows low risk based on this filing. The filing is a routine amendment to a registration statement, with no immediate financial or operational disclosures that would suggest high risk.

Analyst Insight

Monitor future filings for details on the securities offering and the company's strategic plans.

Key Numbers

• 333-278197 — SEC File Number (Registration Statement No.)
• 2024-04-19 — Filing Date (Date filed)
• 1933 — Securities Act (Act under which registration is filed)
• 2834 — SIC Code (Pharmaceutical Preparations)

Key Players & Entities

• Cyclacel Pharmaceuticals, Inc. (company) — Registrant
• 200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922 (location) — Principal executive offices address
• XCYTE THERAPIES INC (company) — Former company name
• 2000-12-18 (date) — Date of name change
• Spiro Rombotis (person) — President & Chief Executive Officer
• Joel I. Papernik, Esq. (person) — Copies to
• Charles Phillips, Esq. (person) — Copies to
• Jeffrey P. Schultz, Esq. (person) — Copies to

FAQ

Industry Context

Cyclacel Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on the development of drugs.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of new securities offerings in the United States.

What Investors Should Do

1. Review the full S-1/A filing for details on the securities being registered.
2. Track future SEC filings from Cyclacel Pharmaceuticals for updates on offering status and company developments.
3. Analyze the company's business strategy and financial health in conjunction with this registration filing.

Key Dates

• 2024-04-19: Filing of Amendment No. 1 to Form S-1 — Updates registration statement for securities.
• 2000-12-18: Name Change — Former name XCYTE THERAPIES INC changed to Cyclacel Pharmaceuticals, Inc.

Year-Over-Year Comparison

This is an amendment to a previously filed S-1 registration statement, indicating ongoing regulatory processes for securities.

Key Financial Figures

• $1.68 — sumed combined public offering price of $1.68 per share of common stock and accompany
• $0.0001 — common stock in this offering less the $0.0001 per share exercise price of each such p
• $1.6799 — ffering price per pre-funded warrant of $1.6799 and accompanying Common Stock Warrants.
• $2,500,000 — Capital Market to maintain a minimum of $2,500,000 in stockholders&rsquo; equity for conti
• $607,000 — o;). Our stockholders&rsquo; equity was $607,000 as of December 31, 2023 and, as a resul
• $3.4 million — e that our cash and cash equivalents of $3.4 million as of December 31, 2023 will allow us t
• $2.7 million — cash balance on hand was approximately $2.7 million. There is no guarantee that we will be
• $0 — d to the public in this offering, minus $0.0001, and the exercise price of each pr

Filing Documents

• tm249520d2_s1.htm (S-1/A) — 584KB
• tm249520d2_ex1-1.htm (EX-1.1) — 101KB
• tm249520d2_ex4-12.htm (EX-4.12) — 145KB
• tm249520d2_ex4-13.htm (EX-4.13) — 104KB
• tm249520d2_ex5-1.htm (EX-5.1) — 10KB
• tm249520d2_ex10-14.htm (EX-10.14) — 217KB
• tm249520d2_ex10-15.htm (EX-10.15) — 103KB
• tm249520d2_ex23-1.htm (EX-23.1) — 2KB
• tm249520d2_ex-filingfees.htm (EX-FILING FEES) — 49KB
• tm249520d2_s1img001.jpg (GRAPHIC) — 2KB
• tm249520d2_ex5-1img001.jpg (GRAPHIC) — 11KB
• 0001104659-24-049518.txt (&nbsp;) — 1333KB

RISK FACTORS

RISK FACTORS 5 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 7

USE OF PROCEEDS

USE OF PROCEEDS 8 MARKET FOR OUR COMMON STOCK 8 DIVIDEND POLICY 8 CAPITALIZATION 9

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 12 MANAGEMENT AND CORPORATE GOVERNANCE 13 EXECUTIVE AND DIRECTOR COMPENSATION 18 EQUITY COMPENSATION PLAN INFORMATION 21 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 26 DESCRIPTION OF OUR COMMON STOCK 27 DESCRIPTION OF OUR PREFERRED STOCK 28 DESCRIPTION OF OUTSTANDING WARRANTS 36 DESCRIPTION OF THE SECURITIES WE ARE OFFERING 39 PLAN OF DISTRIBUTION 43 DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES 45 LEGAL MATTERS 45 EXPERTS 45 WHERE YOU CAN FIND MORE INFORMATION 45 INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE 46 i You should read this prospectus and any applicable prospectus supplement before making an investment in the securities of Cyclacel Pharmaceuticals, Inc. See &ldquo;Where You Can Find More Information&rdquo; for more information. You should rely only on the information contained in this prospectus or a prospectus supplement. The Company has not authorized anyone to provide you with different information. This document may be used only in jurisdictions where offers and sales of these securities are permitted. You should assume that information contained in this prospectus, or in any prospectus supplement, is accurate only as of any date on the front cover of the applicable document. Our business, financial condition, results of operations and prospects may have changed since that date. Unless otherwise noted in this prospectus, &ldquo;Cyclacel Pharmaceuticals,&rdquo; &ldquo;Cyclacel,&rdquo; &ldquo;the Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our&rdquo; and similar terms refer to Cyclacel Pharmaceuticals, Inc. Smaller Reporting Company - Scaled Disclosure Pursuant to Item 10(f) of Regulation S-K promulgated under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), as indicated herein, we have elected to comply with the scaled disclosure requirements applicabl

View Full Filing

View this S-1/A filing on SEC EDGAR